We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Teva, Medicis Strike Deal On Acne Drug Solodyn

Law360 (March 19, 2009, 12:00 AM EDT) -- Generic-drug maker Teva Pharmaceutical Industries Ltd. will stop shipping a popular anti-acne medication for the time being under a newly announced patent agreement with skin health specialist Medicis Pharmaceutical Corp., the companies announced Thursday.

But Teva has the option to market its generic versions of 45 mg, 90 mg and 135 mg Solodyn under the patent rights belonging to Medicis, commencing in November 2011, according to the drugmakers.

Solodyn is marketed as the first and only oral antibiotic approved to treat the inflamed pimples of moderate-to-severe...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.